Bristol-Myers Squibb Co Financials
Bristol-Myers Squibb Co (BMY) reported $48.2B in revenue for fiscal year 2025, down 0.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Durable cash generation carried the business while earnings volatility and higher leverage came from financing and expense shifts.
With gross margin still at71.1% , net income swung from-$8.9B back to profit in the latest year instead of following a clear sales trend. Because operating cash flow stayed above$14B through that move, the reported loss reads more like pressure below gross profit than a collapse in the business's cash generation.
By the latest year, long-term debt of
This remains a low-capex cash generator: free cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bristol-Myers Squibb Co's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Bristol-Myers Squibb Co, and counted as zero in the overall score.
Bristol-Myers Squibb Co's revenue declined 0.2% year-over-year, from $48.3B to $48.2B. This contraction results in a growth score of 44/100.
Bristol-Myers Squibb Co has elevated debt relative to equity (D/E of 2.32), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 27/100, reflecting increased financial risk.
Bristol-Myers Squibb Co's current ratio of 1.26 indicates adequate short-term liquidity, earning a score of 31/100. The company can meet its near-term obligations, though with limited headroom.
Bristol-Myers Squibb Co converts 26.7% of revenue into free cash flow ($12.8B). This strong cash generation earns a score of 93/100.
Not available for Bristol-Myers Squibb Co, and counted as zero in the overall score.
Bristol-Myers Squibb Co passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Bristol-Myers Squibb Co generates $2.01 in operating cash flow ($14.2B OCF vs $7.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Bristol-Myers Squibb Co generated $48.2B in revenue in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Bristol-Myers Squibb Co reported $7.1B in net income in fiscal year 2025. This represents an increase of 178.8% from the prior year.
Bristol-Myers Squibb Co earned $3.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 178.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bristol-Myers Squibb Co generated $12.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 7.9% from the prior year.
Bristol-Myers Squibb Co held $10.2B in cash against $42.9B in long-term debt as of fiscal year 2025.
Bristol-Myers Squibb Co paid $2.49 per share in dividends in fiscal year 2025. This represents an increase of 2.9% from the prior year.
Margins & Returns
Bristol-Myers Squibb Co's gross margin was 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.
Bristol-Myers Squibb Co's net profit margin was 14.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 33.2 percentage points from the prior year.
Bristol-Myers Squibb Co's ROE was 38.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 93.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Bristol-Myers Squibb Co invested $10.0B in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Bristol-Myers Squibb Co repurchased no shares in fiscal year 2025.
Bristol-Myers Squibb Co invested $1.3B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 5.0% from the prior year.
BMY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.2B | $48.2B-0.2% | $48.3B+7.3% | $45.0B-2.5% | $46.2B-0.5% | $46.4B+9.1% | $42.5B+62.6% | $26.1B+15.9% | $22.6B+8.6% | $20.8B+6.9% | $19.4B+17.3% | $16.6B+4.3% | $15.9B-3.1% | $16.4B-7.0% | $17.6B-17.1% | $21.2B |
| Cost of Revenue | $14.7B | $13.9B-0.2% | $14.0B+30.6% | $10.7B+5.5% | $10.1B+2.0% | $9.9B-15.6% | $11.8B+45.7% | $8.1B+24.9% | $6.5B+7.5% | $6.0B+21.0% | $5.0B+27.1% | $3.9B-0.6% | $3.9B-14.9% | $4.6B+0.2% | $4.6B-17.6% | $5.6B |
| Gross Profit | $34.5B | $34.3B-0.2% | $34.3B+0.1% | $34.3B-4.7% | $36.0B-1.2% | $36.4B+18.5% | $30.7B+70.2% | $18.1B+12.3% | $16.1B+9.6% | $14.7B+1.4% | $14.5B+14.5% | $12.7B+5.9% | $11.9B+1.5% | $11.8B-9.6% | $13.0B-16.8% | $15.6B |
| R&D Expenses | $10.7B | $10.0B-10.8% | $11.2B+20.0% | $9.3B-2.2% | $9.5B-6.7% | $10.2B+1.5% | $10.0B+63.4% | $6.1B-2.9% | $6.3B-2.1% | $6.5B+29.1% | $5.0B-15.3% | $5.9B+30.6% | $4.5B+21.5% | $3.7B-4.4% | $3.9B+1.7% | $3.8B |
| SG&A Expenses | $7.4B | $7.3B-13.6% | $8.4B+8.3% | $7.8B-0.5% | $7.8B+1.6% | $7.7B+0.4% | $7.7B+57.3% | $4.9B+7.0% | $4.6B-4.2% | $4.8B-4.6% | $5.0B+2.9% | $4.8B+0.4% | $4.8B-2.4% | $4.9B+17.0% | $4.2B+0.4% | $4.2B |
| Interest Expense | $1.7B | $1.9B-2.9% | $1.9B+67.0% | $1.2B-5.4% | $1.2B-7.6% | $1.3B-6.1% | $1.4B+116.5% | $656.0M+258.5% | $183.0M-6.6% | $196.0M+17.4% | $167.0M-9.2% | $184.0M-9.4% | $203.0M+2.0% | $199.0M+9.3% | $182.0M+25.5% | $145.0M |
| Income Tax | $2.6B | $2.3B+310.1% | $554.0M+38.5% | $400.0M-70.8% | $1.4B+26.2% | $1.1B-49.0% | $2.1B+40.2% | $1.5B+48.4% | $1.0B-75.4% | $4.2B+195.2% | $1.4B+215.7% | $446.0M+26.7% | $352.0M+13.2% | $311.0M+293.2% | -$161.0M-109.4% | $1.7B |
| Net Income | $9.3B | $7.1B+178.8% | -$8.9B-211.5% | $8.0B+26.8% | $6.3B-9.5% | $7.0B+177.6% | -$9.0B-362.1% | $3.4B-30.1% | $4.9B+388.6% | $1.0B-77.4% | $4.5B+184.8% | $1.6B-21.9% | $2.0B-21.8% | $2.6B+30.8% | $2.0B-47.2% | $3.7B |
| EPS (Diluted) | — | $3.46+178.5% | -$4.41-214.2% | $3.86+30.8% | $2.95-5.4% | $3.12+178.2% | -$3.99-298.5% | $2.01-33.2% | $3.01+393.4% | $0.61-77.0% | $2.65+184.9% | $0.93-22.5% | $1.20-22.1% | $1.54+32.8% | $1.16-46.3% | $2.16 |
Not reported in any period shown, so not listed: Operating Income.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BMY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $90.0B-2.8% | $92.6B-2.7% | $95.2B-1.7% | $96.8B-11.4% | $109.3B-7.7% | $118.5B-8.8% | $129.9B+271.4% | $35.0B+4.3% | $33.6B-0.5% | $33.7B+6.2% | $31.7B-5.9% | $33.7B-12.5% | $38.6B+7.5% | $35.9B+8.9% | $33.0B |
| Current Assets | $29.4B-1.3% | $29.8B-6.3% | $31.8B+16.5% | $27.3B-18.0% | $33.3B+10.2% | $30.2B+2.9% | $29.4B+65.7% | $17.7B+19.3% | $14.9B+8.4% | $13.7B+31.6% | $10.4B-28.7% | $14.6B-22.8% | $18.9B+98.7% | $9.5B-37.8% | $15.3B |
| Cash & Equivalents | $10.2B-1.3% | $10.3B-9.8% | $11.5B+25.7% | $9.1B-34.7% | $14.0B-3.9% | $14.5B+17.8% | $12.3B+78.6% | $6.9B+27.5% | $5.4B+27.9% | $4.2B+77.7% | $2.4B-57.2% | $5.6B+55.4% | $3.6B+116.5% | $1.7B-71.3% | $5.8B |
| Inventory | $2.7B+5.2% | $2.6B-3.9% | $2.7B+13.8% | $2.3B+11.6% | $2.1B+1.0% | $2.1B-51.7% | $4.3B+259.2% | $1.2B+2.5% | $1.2B-6.0% | $1.2B+1.6% | $1.2B-21.7% | $1.6B+4.1% | $1.5B-9.6% | $1.7B+19.7% | $1.4B |
| Accounts Receivable | $9.6B+6.4% | $9.0B+1.5% | $8.9B+9.0% | $8.2B+2.2% | $8.0B+10.5% | $7.2B+11.5% | $6.5B+39.7% | $4.6B+6.6% | $4.3B+15.2% | $3.8B+28.0% | $2.9B+40.4% | $2.1B+24.3% | $1.7B-1.1% | $1.7B-24.1% | $2.3B |
| Goodwill | $21.8B+0.2% | $21.7B+2.6% | $21.2B+0.1% | $21.1B+3.2% | $20.5B-0.2% | $20.5B-8.6% | $22.5B+244.0% | $6.5B-4.7% | $6.9B-0.2% | $6.9B-0.1% | $6.9B-2.1% | $7.0B-1.0% | $7.1B-7.1% | $7.6B+36.7% | $5.6B |
| Total Liabilities | $71.5B-6.1% | $76.2B+16.1% | $65.7B0.0% | $65.7B-10.4% | $73.3B-9.0% | $80.6B+3.0% | $78.2B+275.1% | $20.9B-3.9% | $21.7B+25.0% | $17.4B+0.2% | $17.3B-7.7% | $18.8B-19.7% | $23.4B+4.9% | $22.3B+30.1% | $17.1B |
| Current Liabilities | $23.4B-1.5% | $23.8B+6.8% | $22.3B+1.7% | $21.9B+0.1% | $21.9B+14.6% | $19.1B+4.2% | $18.3B+71.8% | $10.7B+11.4% | $9.6B+8.2% | $8.8B+10.3% | $8.0B-5.2% | $8.5B-32.0% | $12.4B+50.3% | $8.3B+6.4% | $7.8B |
| Long-Term Debt | $42.9B-10.0% | $47.6B+29.9% | $36.7B+4.6% | $35.1B-11.5% | $39.6B-18.1% | $48.3B+11.4% | $43.4B+668.5% | $5.6B-19.1% | $7.0B+22.0% | $5.7B-12.7% | $6.5B-9.6% | $7.2B-9.3% | $8.0B+21.5% | $6.6B+22.2% | $5.4B |
| Total Equity | $18.5B+13.1% | $16.3B-44.5% | $29.4B-5.3% | $31.1B-13.6% | $35.9B-5.0% | $37.8B-26.7% | $51.6B+267.7% | $14.0B+19.5% | $11.7B-27.4% | $16.2B+13.4% | $14.3B-3.9% | $14.9B-2.0% | $15.2B+11.2% | $13.6B-14.6% | $16.0B |
| Retained Earnings | $16.9B+13.3% | $14.9B-48.2% | $28.8B+12.8% | $25.5B+7.1% | $23.8B+11.9% | $21.3B-38.3% | $34.5B+1.2% | $34.1B+9.3% | $31.2B-7.0% | $33.5B+6.0% | $31.6B-2.9% | $32.5B-1.2% | $33.0B+0.7% | $32.7B-1.0% | $33.1B |
BMY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12.8B | $14.2B-6.8% | $15.2B+9.6% | $13.9B+6.1% | $13.1B-19.4% | $16.2B+15.3% | $14.1B+71.2% | $8.2B+16.2% | $7.1B+34.0% | $5.3B+72.5% | $3.1B+45.3% | $2.1B-33.1% | $3.1B-11.2% | $3.5B-48.9% | $6.9B+43.4% | $4.8B |
| Capital Expenditures | $1.3B | $1.3B+5.0% | $1.2B+3.2% | $1.2B+8.1% | $1.1B+14.9% | $973.0M+29.2% | $753.0M-9.9% | $836.0M-12.1% | $951.0M-9.9% | $1.1B-13.2% | $1.2B+48.2% | $820.0M+55.9% | $526.0M-2.0% | $537.0M-2.0% | $548.0M+49.3% | $367.0M |
| Free Cash Flow | $11.4B | $12.8B-7.9% | $13.9B+10.2% | $12.7B+5.9% | $11.9B-21.6% | $15.2B+14.5% | $13.3B+80.3% | $7.4B+20.6% | $6.1B+44.9% | $4.2B+129.0% | $1.8B+43.4% | $1.3B-51.0% | $2.6B-12.8% | $3.0B-52.9% | $6.4B+42.9% | $4.5B |
| Investing Cash Flow | -$4.9B | -$4.1B+80.6% | -$21.4B-830.4% | -$2.3B-116.1% | -$1.1B-97.4% | -$538.0M+95.0% | -$10.9B-9.5% | -$9.9B-395.7% | -$2.0B-2930.3% | -$66.0M-104.5% | $1.5B+194.1% | -$1.6B-229.3% | $1.2B+312.6% | -$572.0M+91.5% | -$6.7B-368.1% | -$1.4B |
| Financing Cash Flow | -$11.7B | -$10.3B-301.8% | $5.1B+154.4% | -$9.4B+44.5% | -$17.0B-4.5% | -$16.2B-1309.6% | -$1.2B-115.1% | $7.6B+315.6% | -$3.5B+13.3% | -$4.1B-53.7% | -$2.7B+26.8% | -$3.6B-48.7% | -$2.4B-128.2% | -$1.1B+75.4% | -$4.3B-63.1% | -$2.7B |
| Dividends Paid | $5.1B | $5.0B+3.7% | $4.9B+2.5% | $4.7B+2.4% | $4.6B+5.4% | $4.4B+7.9% | $4.1B+52.1% | $2.7B+2.5% | $2.6B+1.4% | $2.6B+1.2% | $2.5B+2.8% | $2.5B+3.3% | $2.4B+3.9% | $2.3B+1.0% | $2.3B+1.4% | $2.3B |
| Share Buybacks | N/A | $0 | $0-100.0% | $5.2B-35.6% | $8.0B+27.3% | $6.3B+306.7% | $1.5B-78.8% | $7.3B+2181.3% | $320.0M-87.0% | $2.5B+968.8% | $231.0M | N/A | N/A | $433.0M-82.0% | $2.4B+96.8% | $1.2B |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BMY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.1%0.0pp | 71.1%-5.2pp | 76.2%-1.8pp | 78.0%-0.5pp | 78.6%+6.3pp | 72.3%+3.2pp | 69.1%-2.2pp | 71.3%+0.7pp | 70.7%-3.9pp | 74.5%-1.9pp | 76.4%+1.2pp | 75.2%+3.4pp | 71.8%-2.0pp | 73.8%+0.2pp | 73.7% |
| Net Margin | 14.6%+33.2pp | -18.5%-36.4pp | 17.8%+4.1pp | 13.7%-1.4pp | 15.1%+36.3pp | -21.2%-34.4pp | 13.2%-8.7pp | 21.8%+17.0pp | 4.9%-18.1pp | 22.9%+13.5pp | 9.4%-3.2pp | 12.6%-3.0pp | 15.6%+4.5pp | 11.1%-6.3pp | 17.5% |
| Return on Equity | 38.2%+93.0pp | -54.8%-82.0pp | 27.3%+6.9pp | 20.4%+0.9pp | 19.5%+43.3pp | -23.8%-30.5pp | 6.7%-28.4pp | 35.1%+26.5pp | 8.6%-19.0pp | 27.6%+16.6pp | 11.0%-2.5pp | 13.5%-3.4pp | 16.9%+2.5pp | 14.4%-8.9pp | 23.3% |
| Return on Assets | 7.8%+17.5pp | -9.7%-18.1pp | 8.4%+1.9pp | 6.5%+0.1pp | 6.4%+14.0pp | -7.6%-10.3pp | 2.6%-11.4pp | 14.1%+11.1pp | 3.0%-10.2pp | 13.2%+8.3pp | 4.9%-1.0pp | 5.9%-0.7pp | 6.6%+1.2pp | 5.5%-5.8pp | 11.3% |
| Current Ratio | 1.260.0x | 1.25-0.2x | 1.43+0.2x | 1.25-0.3x | 1.52-0.1x | 1.580.0x | 1.60-0.1x | 1.66+0.1x | 1.550.0x | 1.55+0.3x | 1.30-0.4x | 1.73+0.2x | 1.52+0.4x | 1.15-0.8x | 1.97 |
| Debt-to-Equity | 2.32-0.6x | 2.91+1.7x | 1.25+0.1x | 1.130.0x | 1.10-0.2x | 1.28+0.4x | 0.84+0.4x | 0.40-0.2x | 0.59+0.2x | 0.35-0.1x | 0.460.0x | 0.490.0x | 0.530.0x | 0.48+0.1x | 0.34 |
| FCF Margin | 26.7%-2.2pp | 28.9%+0.8pp | 28.1%+2.2pp | 25.9%-7.0pp | 32.8%+1.6pp | 31.3%+3.1pp | 28.2%+1.1pp | 27.1%+6.8pp | 20.3%+10.8pp | 9.5%+1.7pp | 7.8%-8.8pp | 16.5%-1.9pp | 18.4%-17.9pp | 36.3%+15.2pp | 21.1% |
Not reported in any period shown, so not listed: Operating Margin.
Similar Companies
Where Bristol-Myers Squibb Co Ranks
Frequently Asked Questions
What is Bristol-Myers Squibb Co's annual revenue?
Bristol-Myers Squibb Co (BMY) reported $48.2B in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bristol-Myers Squibb Co's revenue growing?
Bristol-Myers Squibb Co (BMY) revenue declined by 0.2% year-over-year, from $48.3B to $48.2B in fiscal year 2025.
Is Bristol-Myers Squibb Co profitable?
Yes, Bristol-Myers Squibb Co (BMY) reported a net income of $7.1B in fiscal year 2025, with a net profit margin of 14.6%.
How much debt does Bristol-Myers Squibb Co have?
As of fiscal year 2025, Bristol-Myers Squibb Co (BMY) had $10.2B in cash and equivalents against $42.9B in long-term debt.
What is Bristol-Myers Squibb Co's gross margin?
Bristol-Myers Squibb Co (BMY) had a gross margin of 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bristol-Myers Squibb Co's net profit margin?
Bristol-Myers Squibb Co (BMY) had a net profit margin of 14.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Bristol-Myers Squibb Co pay dividends?
Yes, Bristol-Myers Squibb Co (BMY) paid $2.49 per share in dividends during fiscal year 2025.
What is Bristol-Myers Squibb Co's return on equity (ROE)?
Bristol-Myers Squibb Co (BMY) has a return on equity of 38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bristol-Myers Squibb Co's free cash flow?
Bristol-Myers Squibb Co (BMY) generated $12.8B in free cash flow during fiscal year 2025. This represents a -7.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bristol-Myers Squibb Co's operating cash flow?
Bristol-Myers Squibb Co (BMY) generated $14.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bristol-Myers Squibb Co's total assets?
Bristol-Myers Squibb Co (BMY) had $90.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bristol-Myers Squibb Co's capital expenditures?
Bristol-Myers Squibb Co (BMY) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bristol-Myers Squibb Co spend on research and development?
Bristol-Myers Squibb Co (BMY) invested $10.0B in research and development during fiscal year 2025.
What is Bristol-Myers Squibb Co's current ratio?
Bristol-Myers Squibb Co (BMY) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.
What is Bristol-Myers Squibb Co's debt-to-equity ratio?
Bristol-Myers Squibb Co (BMY) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bristol-Myers Squibb Co's return on assets (ROA)?
Bristol-Myers Squibb Co (BMY) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bristol-Myers Squibb Co's Piotroski F-Score?
Bristol-Myers Squibb Co (BMY) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bristol-Myers Squibb Co's earnings high quality?
Bristol-Myers Squibb Co (BMY) has an earnings quality ratio of 2.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bristol-Myers Squibb Co?
Bristol-Myers Squibb Co (BMY) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.